A new collaboration involving major pharmaceutical and healthcare companies, including API, Novartis and Abbott, is seeking to increase access to screening for cardiovascular risk factors.
Major new collaboration launches CV screening pilot with national ambitions
September 28, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Outcomes published from meeting the PBAC was directed to hold
June 22, 2025 - - Latest News -
TGA-licensed compounders call for review to ensure sustainability
June 20, 2025 - - Latest News -
GLP-1 pill study marks potential new chapter in treating diabetes and weight loss
June 20, 2025 - - Latest News -
An ideological darkness underpins our system's decision-making
June 20, 2025 - - Latest News -
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma